| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.059 | 0.3 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.3 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.3 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.3 |